Kronos Bio IncNASDAQ:KRON
- LAST PRICE0.9830
- TODAY'S CHANGE (%)0.0016 (0.1630%)
- Bid / Lots0.9830/ 1
- Ask / Lots0.9922/ 6
- Open / Previous Close0.9900 / 0.9814
- Day Range
- 52 Week Range
- Volume93,215
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KRON |
|---|---|---|
| 09:32 ET | 3063 | 0.9895 |
| 09:34 ET | 1000 | 0.99 |
| 09:36 ET | 161 | 0.9895 |
| 09:38 ET | 3100 | 0.98 |
| 09:43 ET | 554 | 0.98 |
| 09:48 ET | 100 | 0.982 |
| 09:50 ET | 100 | 0.982 |
| 09:54 ET | 100 | 0.983 |
| 09:57 ET | 1100 | 0.983 |
| 09:59 ET | 3242 | 0.9988 |
| 10:03 ET | 38513 | 0.999 |
| 10:08 ET | 100 | 0.9899 |
| 10:12 ET | 100 | 0.9899 |
| 10:14 ET | 1000 | 0.9899 |
| 10:15 ET | 100 | 0.99 |
| 10:19 ET | 100 | 0.9989 |
| 10:21 ET | 100 | 0.999 |
| 10:28 ET | 200 | 0.995 |
| 10:35 ET | 100 | 0.995 |
| 10:44 ET | 1100 | 0.998 |
| 10:55 ET | 100 | 0.9949 |
| 10:57 ET | 100 | 0.9912 |
| 11:04 ET | 2436 | 0.991 |
| 11:08 ET | 300 | 0.9944 |
| 11:11 ET | 13100 | 0.99 |
| 11:13 ET | 2300 | 0.99 |
| 11:18 ET | 100 | 0.99 |
| 11:24 ET | 100 | 0.99 |
| 11:26 ET | 8405 | 0.9857 |
| 11:27 ET | 1095 | 0.982 |
| 11:33 ET | 100 | 0.982 |
| 11:38 ET | 100 | 0.982 |
| 11:42 ET | 175 | 0.988449 |
| 11:44 ET | 100 | 0.982 |
| 11:45 ET | 100 | 0.99245 |
| 11:49 ET | 200 | 0.982 |
| 11:51 ET | 371 | 0.982 |
| 11:56 ET | 100 | 0.99245 |
| 11:58 ET | 1700 | 0.9899 |
| 12:03 ET | 100 | 0.982 |
| 12:07 ET | 100 | 0.99245 |
| 12:09 ET | 100 | 0.982 |
| 12:16 ET | 100 | 0.982 |
| 12:18 ET | 100 | 0.982 |
| 12:21 ET | 100 | 0.99245 |
| 12:23 ET | 200 | 0.9828 |
| 12:25 ET | 3449 | 0.982901 |
| 12:30 ET | 400 | 0.9828 |
| 12:38 ET | 200 | 0.99125 |
| 12:43 ET | 100 | 0.9828 |
| 12:52 ET | 100 | 0.983 |
| 12:59 ET | 100 | 0.983 |
| 01:06 ET | 100 | 0.983 |
| 01:12 ET | 100 | 0.983 |
May 9, 2024
*DJ Kronos Bio 1Q Loss/Shr 50c >KRON, from 4:06PM ET on Thursday May 09, 2024 by Dow Jones
4:06PM ET on Thursday May 09, 2024 by Dow JonesKronos Bio Reports First-Quarter 2024 Financial Results, from 4:06PM ET on Thursday May 09, 2024 by Dow Jones
4:06PM ET on Thursday May 09, 2024 by Dow Jones
May 3, 2024
DJ Kronos Bio Is Maintained at Buy by HC Wainwright & Co., from 4:11PM ET on Friday May 03, 2024 by Dow Jones
4:11PM ET on Friday May 03, 2024 by Dow Jones
Apr 24, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kronos Bio Inc | 59.0M | -0.5x | --- |
Kezar Life Sciences Inc | 56.2M | -0.6x | --- |
BioLine RX Ltd | 53.0M | -0.7x | --- |
LAVA Therapeutics NV | 74.4M | -1.8x | --- |
Correlate Energy Corp | 48.5M | -3.4x | --- |
Ikena Oncology Inc | 64.4M | -0.9x | --- |
Company Information
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
Contact Information
- Headquarters
- 1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402
- Phone
- 650-781-5200
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- Arie Belldegrun
- Director
- Norbert Bischofberger
- Interim Chief Financial Officer
- Sandra Gardiner
- Chief Scientific Officer
- Christopher Dinsmore
- Director
- Joshua Kazam
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $59.0M |
|---|---|
Revenue (TTM) | $7.6M |
Shares Outstanding | 60.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-2.00 |
Book Value | $2.70 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 7.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,651.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
